Abstract Subcutaneous ICD (S-ICD™) therapy has been established in initial clinical trials
and current international guideline recommendations for patients without demand for …

Background The subcutaneous implantable cardioverter-defibrillator (S-ICD) is an
alternative to conventional transvenous ICD (TV-ICD) therapy to reduce lead complications …

Background Adult congenital heart disease (ACHD) patients can benefit from a
subcutaneous implantable cardioverter-defibrillator (S-ICD). Objective The purpose of this …

Aims Patients with adult congenital heart disease (ACHD) carry an increased risk for sudden
cardiac death. Implantable cardioverter‐defibrillator (ICD) therapy may be challenging in …

Background The study sought to assess the prognostic impact of chronic kidney disease
(CKD) and renal replacement therapy (RRT) in patients with ventricular tachyarrhythmias …

An implantable cardioverter-defibrillator (ICD) was developed to provide protection against
sudden cardiac death. Despite being effective in terminating ventricular arrhythmias …

Purpose The study sought to evaluate the prognostic impact of recurrences of ventricular
tachyarrhythmias in consecutive ICD recipients with ventricular tachyarrhythmias on …

Background and Objectives: Subcutaneous implantable cardioverter-defibrillators (S-ICDs)
provide protection against sudden cardiac death from outside the cardiovascular system …

Introduction Patients with hypertrophic cardiomyopathy (HCM) relatively often fail
preimplantation ECG screening for subcutaneous implantable cardioverter-defibrillator (S …

Abstract Introduction Between 7% and 15% of patients with an indication for an implantable
cardioverter‐defibrillator (ICD) are not eligible for implantation of a subcutaneous …